e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2005
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-18443
|
|
52-1574808 |
|
|
|
|
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification Number) |
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip Code)
(602) 808-8800
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On November 8, 2005, Medicis Pharmaceutical Corporation issued a press release announcing its
financial results for the quarter ended September 30, 2005. A copy of the press release is
furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Current Report, including the accompanying exhibit, is being furnished
and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section. The information in this
Current Report shall not be incorporated by reference into any registration statement or other
document filed pursuant to the Securities Act of 1933, as amended, regardless of any general
incorporation language in such filing.
Item 9.01 Exhibits.
(c) Exhibits
99.1 Press Release dated November 8, 2005
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 8, 2005
|
|
|
|
|
|
MEDICIS PHARMACEUTICAL CORPORATION
|
|
|
By: |
/s/ Mark A. Prygocki, Sr.
|
|
|
|
Mark A. Prygocki, Sr. |
|
|
|
Executive Vice President, Chief Financial
Officer, Corporate Secretary and Treasurer |
|
Exhibit Index
|
|
|
Exhibit Number |
|
Description |
|
|
|
99.1
|
|
Press Release dated November 8, 2005 |